Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04787471
PHASE2/PHASE3

Corneal Crosslinking for Treatment of Corneal Neovascularization

Sponsor: Price Vision Group

View on ClinicalTrials.gov

Summary

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Official title: Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

62

Start Date

2021-05-03

Completion Date

2026-09-15

Last Updated

2025-07-31

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

30 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 3mW/cm2 UVA light for 30 minutes

COMBINATION_PRODUCT

10 minute photoactivation of riboflavin 0.1%

Use of riboflavin 0.1% eye drops and 9mW/cm2 UVA light for 10 minutes

Locations (1)

Price Vision Group

Indianapolis, Indiana, United States